Shares now up at $41.85 (EXAC) ALERT: Rowley Law PLLC is Investigating…

0
37

Exactech, Inc. (NASDAQ:EXAC):

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Exactech.

In the market the company is trading up from yesterday’s close of 32.

Exactech, Inc. (Exactech), launched on November 13, 1985, develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally. The Business’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines. The Company distributes joint replacement systems, including knee, hip, spine and extremity implant systems, and biologic products and services and bone cement materials used in orthopedic surgery and dental procedures..

The stock is trading at $41.85 quite a bit higher than the 50 day moving average of $32.18 and which is well above the 200 day moving average of $30.28. The 50 day moving average went up by +30.07% and the 200 day average moved up $11.57.

Exactech, Inc. currently has a P/E ratio of 804.81 and market capitalization is 600.46M. In the last earnings report the EPS was $0.05 and is expected to be $1.29 for the current year with 14,348,000 shares outstanding. Next quarter’s EPS is estimated at $0.39 and the next full year EPS is projected to be $1.47.

Short traders are more bullish on shares of Exactech, Inc. of late if you watch the fall in short interest. The firm experienced a fall in short interest of -6.78% between September 15, 2017 and September 29, 2017. Short shares fell 8,442 over that timeframe. With short interest at 116,038 and short average daily volume at 30,690, days to cover is 4.0 and the short interest percentage is 0.01% as of September 29.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.